MITOMYCIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H18N4O5
Molecular Weight	334.3272
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CO[C@]12[C@H]3N[C@H]3CN1C4=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C4=O

InChI

InChIKey=NWIBSHFKIJFRCO-WUDYKRTCSA-N

InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C15H18N4O5
Molecular Weight	334.3272
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a1300e9-ca6e-4713-b41a-bb913aed3287
Curator's Comment: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00305 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022572s003lbl.pdf https://en.wikipedia.org/wiki/Mitomycins

The mitomycins are a family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae. One of these compounds, mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour activity. Mitomycin C has also been used topically rather than intravenously in several areas. The first is cancers, particularly bladder cancers and intraperitoneal tumours. It is now well known that a single instillation of this agent within 6 hours of bladder tumor resection can prevent recurrence. The second is in eye surgery where mitomycin C 0.02% is applied topically to prevent scarring during glaucoma filtering surgery and to prevent haze after PRK or LASIK; mitomycin C has also been shown to reduce fibrosis in strabismus surgery. The third is in esophageal and tracheal stenosis where application of mitomycin C onto the mucosa immediately following dilatation will decrease re-stenosis by decreasing the production of fibroblasts and scar tissue. Mitomycin C is a potent DNA crosslinker. A single crosslink per genome has shown to be effective in killing bacteria. This is accomplished by reductive activation of mitomycin to form a mitosene, which reacts successively via N-alkylation of two DNA bases. Both alkylations are sequence specific for a guanine nucleoside in the sequence 5'-CpG-3'. Potential bis-alkylating heterocylic quinones were synthetised in order to explore their antitumoral activities by bioreductive alkylation. Mitomycin is also used as a chemotherapeutic agent in glaucoma surgery.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 282 Target ID: CHEMBL2311221 Sources: http://www.drugbank.ca/drugs/DB00305	Crosslinking Agent 83

Conditions

Condition	Modality	Highest Phase	Product
Glaucoma surgery 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022572s003lbl.pdf	Secondary	Approved 8583	MITOSOL Approved Use is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery Launch Date 2012
Disseminated adenocarcinoma of the stomach 1 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a1300e9-ca6e-4713-b41a-bb913aed3287	Palliative	Approved 8583	MITOMYCIN Approved Use Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. Launch Date 2012
Adenocarcinoma of pancreas 1 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a1300e9-ca6e-4713-b41a-bb913aed3287	Palliative	Approved 8583	MITOMYCIN Approved Use Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. Launch Date 2012

AUC

Value	Dose	Co-administered	Analyte	Population
773 μg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3097025	10 mg/m² single, intravenous dose: 10 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		MITOMYCIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
630 μg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/6411336	10 mg/m² single, intravenous dose: 10 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		MITOMYCIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
54 min EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3097025	10 mg/m² single, intravenous dose: 10 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		MITOMYCIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
50 min EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/6411336	10 mg/m² single, intravenous dose: 10 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		MITOMYCIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
76% EXPERIMENT https://scialert.net/fulltextmobile/?doi=ijp.2006.293.297			MITOMYCIN plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
3.2 mg/m2 1 times / day multiple, intravenous MTD Dose: 3.2 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 3.2 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16142489	unhealthy, 36.2 - 68.0 Health Status: unhealthy Age Group: 36.2 - 68.0 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/16142489	Sources: https://pubmed.ncbi.nlm.nih.gov/16142489
4 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 4 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 4 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16142489	unhealthy, 36.2 - 68.0 Health Status: unhealthy Age Group: 36.2 - 68.0 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/16142489	DLT: Dysphagia, Mucositis... Dose limiting toxicities: Dysphagia (grade 3, 16.7%) Mucositis (grade 3, 33.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/16142489
6 mg/m2 1 times / 4 weeks multiple, intravenous MTD Dose: 6 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 6 mg/m2, 1 times / 4 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/10678557	unhealthy, 53-71 Health Status: unhealthy Age Group: 53-71 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10678557	DLT: Febrile neutropenia, Hyponatremia... Dose limiting toxicities: Febrile neutropenia (grade 4, 33.3%) Hyponatremia (grade 3, 33.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/10678557
15 mg/m2 single, intravenous Recommended Dose: 15 mg/m2 Route: intravenous Route: single Dose: 15 mg/m2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50763_Mitozytrex_lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50763_Mitozytrex_lbl.pdf	Disc. AE: Bone marrow depression, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Bone marrow depression Thrombocytopenia Leukopenia Hemolytic uremic syndrome Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50763_Mitozytrex_lbl.pdf

AEs

AE	Significance	Dose	Population
Dysphagia	grade 3, 16.7% DLT	4 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 4 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 4 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16142489	unhealthy, 36.2 - 68.0 Health Status: unhealthy Age Group: 36.2 - 68.0 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/16142489
Mucositis	grade 3, 33.3% DLT	4 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 4 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 4 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16142489	unhealthy, 36.2 - 68.0 Health Status: unhealthy Age Group: 36.2 - 68.0 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/16142489
Hyponatremia	grade 3, 33.3% DLT	6 mg/m2 1 times / 4 weeks multiple, intravenous MTD Dose: 6 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 6 mg/m2, 1 times / 4 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/10678557	unhealthy, 53-71 Health Status: unhealthy Age Group: 53-71 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10678557
Febrile neutropenia	grade 4, 33.3% DLT	6 mg/m2 1 times / 4 weeks multiple, intravenous MTD Dose: 6 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 6 mg/m2, 1 times / 4 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/10678557	unhealthy, 53-71 Health Status: unhealthy Age Group: 53-71 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10678557
Bone marrow depression	Disc. AE	15 mg/m2 single, intravenous Recommended Dose: 15 mg/m2 Route: intravenous Route: single Dose: 15 mg/m2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50763_Mitozytrex_lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50763_Mitozytrex_lbl.pdf
Hemolytic uremic syndrome	Disc. AE	15 mg/m2 single, intravenous Recommended Dose: 15 mg/m2 Route: intravenous Route: single Dose: 15 mg/m2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50763_Mitozytrex_lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50763_Mitozytrex_lbl.pdf
Leukopenia	Disc. AE	15 mg/m2 single, intravenous Recommended Dose: 15 mg/m2 Route: intravenous Route: single Dose: 15 mg/m2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50763_Mitozytrex_lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50763_Mitozytrex_lbl.pdf
Thrombocytopenia	Disc. AE	15 mg/m2 single, intravenous Recommended Dose: 15 mg/m2 Route: intravenous Route: single Dose: 15 mg/m2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50763_Mitozytrex_lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50763_Mitozytrex_lbl.pdf

Sourcing

Vendor/Aggregator	ID	URL
abcr GmbH	AB354193	http://www.abcr.com/shop/en/AB354193
AbMole Bioscience	M5791	http://www.abmole.com/products/mitomycin-c.html
Achemtek	0102-012412	http://www.achemtek.com/50-07-7
Achemtek	0104-042208	http://www.achemtek.com/57-07-7
Acorn PharmaTech	ACN-038344	http://www.acornpharmatech.com/
Acros Organics	AC226940020	https://www.fishersci.com/shop/products/mitomycin-c-contains-2-mg-mitomycin-c-48-mg-nacl-acros-organics/AC226940020
AHH Chemical co.,ltd	MT-54310	http://www.ahhchemical.com/product/MT-54310.html
AK Scientific, Inc. (AKSCI)	67474	http://www.aksci.com/item_detail.php?cat=67474
Alsachim	4960	http://www.alsachim.com/product-C6349-glo.bal-view.html
ApexBio Technology	A4452	http://www.apexbt.com/mitomycin-c.html
Aurora Fine Chemicals LLC	A17.878.168	http://online.aurorafinechemicals.com/info?ID=A17.878.168
Aurum Pharmatech LLC	W-5071	http://www.Aurumpharmatech.com/Product/ProductDetails/W_5071
AvaChem Scientific	1996	http://www.avachem.com/productSearch.asp?1996
Avantor Inc	TCM2320-10MG	https://us.vwr.com/store/product/16813418/mitomycin-c-98-0-by-hplc
Avantor Inc	TCM2320-50MG	https://us.vwr.com/store/product/16813418/mitomycin-c-98-0-by-hplc
BioCrick	BCC2388	http://www.biocrick.com/Mitomycin-C-BCC2388.html
BioSynth	Q-201410	https://www.biosynth.com/en/products/life-science/culture-media-additives/products/Q-201410.html
Boerchem	BC208285	http://www.boerchem.com/?product_35217.html
Calbiochem	475820	http://www.emdbiosciences.com/product/475820
Calbiochem	47589	http://www.emdbiosciences.com/product/47589
Chem Scene	CS-0564	http://www.chemscene.com/50-07-7.html
Chemodex	M0161	http://www.chemodex.com/products/M0161
Chemspace	CSSB00000038980	https://chem-space.com/CSSB00000038980
DC Chemicals	DC8935	http://www.dcchemicals.com/product_show-Mitomycin_C.html
EMD Millipore	475820	http://www.emdbiosciences.com/product/475820
EMD Millipore	47589	http://www.emdbiosciences.com/product/47589
Excenen	EX-A501	http://www.excenen.com/searchresultlist.php?id=50-07-7
Glentham Life Sciences	GA9147	http://www.glentham.com/products/product/GA9147/
Hello Bio	HB4458	https://www.hellobio.com/mitomycin-c.html
LGC Standards	DRE-A15273000AL-100	https://www.lgcstandards.com/US/en/p/DRE-A15273000AL-100
LGC Standards	DRE-C15273000	https://www.lgcstandards.com/US/en/p/DRE-C15273000
LGC Standards	LGCFOR1308.00	https://www.lgcstandards.com/US/en/p/LGCFOR1308.00
LGC Standards	MM1308.00	https://www.lgcstandards.com/US/en/p/MM1308.00
MedChem Express	HY-13316	https://www.medchemexpress.com/Mitomycin-C.html
Molcore	MC418475	https://www.molcore.com/product/50-07-7
MuseChem	A000102	https://www.musechem.com/product/A000102.html
OChem	4283	http://www.ocheminc.com/index.php?act=psearch&pid=078M109
Sigma-Aldrich	69824_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/69824?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	M0440_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/m0440?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	M0503_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/m0503?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	M4287_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/m4287?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	M7949_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/m7949?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S535542	http://www.smolecule.com/products/s535542
Synchem UG and Co KG	67389	http://www.synchem.de/chemical_Mitomycin.html
TCI (Tokyo Chemical Industry)	M2320	http://www.tcichemicals.com/eshop/en/us/commodity/M2320/index.html
THE BioTek	bt-275325	https://www.thebiotek.com/product/inhibitors/bt-275325
Tocris	3258	https://www.tocris.com/products/mitomycin-c_3258
Yuhao Chemical	LT7427	http://www.chemyuhao.com/50-07-7.html

PubMed

Title	Date	PubMed
The mouse lymphoma assay detects recombination, deletion, and aneuploidy.	2009-05	19237551
A stable and sensitive testing system for potential carcinogens based on DNA damage-induced gene expression in human HepG2 cell.	2009-02	19013231
Differential expression of TP53 associated genes in Fanconi anemia cells after mitomycin C and hydroxyurea treatment.	2008-10-30	18647660
Vesicoenteric, vesicovaginal, vesicocutaneous fistula -an unusual complication with intravesical mitomycin.	2008-10	18814818
Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer.	2008-09-02	18728667
Splicing and splice factor SRp55 participate in the response to DNA damage by changing isoform ratios of target genes.	2008-08-15	18571879
Hemolytic uremic syndrome.	2008-07	18591164
Mitomycin C induces apoptosis in cultured corneal fibroblasts derived from type II granular corneal dystrophy corneas.	2008-06-30	18615204
Mdm2 as a sensitive and mechanistically informative marker for genotoxicity induced by benzo[a]pyrene and dibenzo[a,l]pyrene.	2008-04	18096571
[Expression of survivin mRNA and protein in mitomycin-treated hepatoma carcinoma Hepa1-6 cells].	2008-02	18250050
Mitomycin C induces multidrug resistance in glaucoma surgery.	2008-02	17934748
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.	2007-12-03	18000507
Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs.	2007-09-20	17878523
The apoptotic effect of intercalating agents on HPV-negative cervical cancer C-33A cells.	2007-07	17021654
Mitomycin-DNA adducts induce p53-dependent and p53-independent cell death pathways.	2007-06-15	17530733
Expression of X-linked inhibitor of apoptosis protein and its effect on chemotherapeutic sensitivity of bladder carcinoma.	2007-06	17641843
Methylation of Ras association domain family protein 1, isoform A correlated with proliferation and drug resistance in hepatocellular carcinoma cell line SMMC-7721.	2007-05	17444856
Calreticulin exposure dictates the immunogenicity of cancer cell death.	2007-01	17187072
Comparison of the mutagenic potential of 17 physical and chemical agents analyzed by the flow cytometry mutation assay.	2006-12-01	17045307
Re-evaluation of tumor-specific cytotoxicity of mitomycin C, bleomycin and peplomycin.	2006-11-11	17094455
[Effect of adenovirus-mediated mutant exogenous P27kip1 gene expression on the chemosensitivities of cholangiocarcinoma cell line].	2006-10-01	17217824
Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells.	2006-10	16957513
Stable formation of mutated p53 multimers in a Chinese hamster cell line causes defective p53 nuclear localization and abrogates its residual function.	2006-08-15	16598767
Arsenite pretreatment enhances the cytotoxicity of mitomycin C in human cancer cell lines via increased NAD(P)H quinone oxidoreductase 1 expression.	2006-08-01	16494910
Mitomycin C induces apoptosis via Fas/FasL dependent pathway and suppression of IL-18 in cervical carcinoma cells.	2006-06-08	16019139
Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits.	2006-06	16805119
Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations.	2006-04-01	16217747
Effects of mitomycin-C on normal dermal fibroblasts.	2006-04	16585851
O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C.	2006-03-01	16039682
TCDD as a biological response modifier for Mitomycin C: oxygen tension affects enzyme activation, reactive oxygen species and cell death.	2006-02-23	16226770
Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines.	2006-02	16568373
Drug-induced thrombotic microangiopathy.	2005-12	16388419
Mitomycin-C induces the apoptosis of human Tenon's capsule fibroblast by activation of c-Jun N-terminal kinase 1 and caspase-3 protease.	2005-10	16186332
Trypan blue identifies antimetabolite treatment area in trabeculectomy.	2005-09	16113371
Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1.	2005-08-10	15756676
Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells.	2005-07-29	15905174
Chloramphenicol-induced mitochondrial stress increases p21 expression and prevents cell apoptosis through a p21-dependent pathway.	2005-07-15	15905168
Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac.	2005-03-28	15793875
Otologic effects of topical mitomycin C: phase I-evaluation of ototoxicity.	2005-03	15793395
Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells.	2005-02	15655414
In vitro effect of cyclosporin A, mitomycin C and prednisolone on cell kinetics in cultured human umbilical vein endothelial cells.	2005	15617745
Effect of in vitro and in vivo treatment with mitomycin C on activities of CYP2D1/2, CYP2C11, and CYP1A2 in rat liver.	2004-11	15696929
Therapeutic effects of Lycium barbarum polysaccharide (LBP) on mitomycin C (MMC)-induced myelosuppressive mice.	2004-10	15724837
Glomerular tuft ballooning in mitomycin-C-induced renal impairment.	1992	1609513
[Microangiopathic hemolytic anemia associated with mitomycin-C treatment].	1991-12	1782316
[Calcified bladder lesions secondary to the instillation of mitomycin C].	1991-11	1807206
[Eosinophilic cystitis as a special form of response to mitomycin C. Analysis and comments on our cases].	1991-10	1796854
[Effect of intraarterial noradrenaline-induced hypertensive chemotherapy of hepatic metastasis in gastric cancer].	1991-08	1908657
Case report: topical DMSO for mitomycin-C-induced skin ulceration.	1991-05-01	1906166
Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells.	1990-12-01	1701346

Patents

Sample Use Guides

In Vivo Use Guide

Sponges provided within the Mitosol ® Kit should be fully saturated with the entire reconstituted contents. A treatment area approximating 10 mm x 6 mm +/- 2 mm should be treated with the Mitosol®.

Route of Administration: Topical

In Vitro Use Guide

The molecular mechanism of differentiation interruption by mitomycin C in the Non-small-cell lung cancer (NSCLC) line A549 was investigated. High dosage of mitomycin C (300 µM) could significantly inhibit cell proliferation (P < 0.05) by 48.39 ± 3.32% (P < 0.05), under which cell shrinkage and disruption were observed

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:56:26 GMT 2025` Edited by `admin` on `Mon Mar 31 17:56:26 GMT 2025`
Record UNII	50SG953SK6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MITOMYCIN C

Preferred Name

English

MITOMYCIN

Official Name

English

MITOMYCIN C [IARC]

Common Name

English

MITOMYCIN [USAN]

Common Name

English

AMETYCINE

Brand Name

English

MITOMYCIN C [JAN]

Common Name

English

UGN-101

Code

English

JELMYTO

Brand Name

English

MITOMYCIN [HSDB]

Common Name

English

MITOMYCIN [VANDF]

Common Name

English

MITOMYCIN [USP MONOGRAPH]

Common Name

English

MITOMYCIN C [MI]

Common Name

English

mitomycin [INN]

Common Name

English

MUAMYCIN

Brand Name

English

MUTAMYCIN

Brand Name

English

MITOCIN-C

Brand Name

English

Mitomycin [WHO-DD]

Common Name

English

6-AMINO-1,1A,2,8,8A,8B-HEXAHYDRO-8-(HYDROXYMETHYL)-8A-METHOXY-5-METHYLAZIRINO(2',3':3,4)PYRROLO(1,2-A)INDOLE-4,7-DIONE CARBAMATE (ESTER)

Common Name

English

UGN-102

Code

English

MITOSOL

Brand Name

English

MITOMYCIN [MART.]

Common Name

English

MYTOZYTREX

Brand Name

English

AZIRINO(2',3':3,4)PYRROLO(1,2-A)INDOLE-4,7-DIONE, 6-AMINO-8-(((AMINOCARBONYL)OXY)METHYL)-1,1A,2,8,8A,8B-HEXAHYDRO-8A-METHOXY-5-METHYL-, (1AS-(1A.ALPHA.,8.BETA.,8A.ALPHA.,8B.ALPHA.))-

Common Name

English

MITOMYCIN [ORANGE BOOK]

Common Name

English

MITOMYCIN [USP-RS]

Common Name

English

MITOMYCIN [EP MONOGRAPH]

Common Name

English

MITOMYCIN-C

Common Name

English

NSC-26980

Code

English

Classification Tree Code System Code

FDA ORPHAN DRUG

312510